Palatin Technologies (NYSEAMERICAN:PTN) Posts Quarterly Earnings Results

Palatin Technologies (NYSEAMERICAN:PTN) announced its earnings results on Wednesday. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.87, FiscalAI reports. The firm had revenue of $3.92 million during the quarter, compared to analyst estimates of $1.28 million.

Here are the key takeaways from Palatin Technologies’ conference call:

• Palatin said its once-weekly MC4R-selective peptide obesity program remains on track for an IND submission in Q4 2026, and management said the candidate has entered IND-enabling studies.
• The company highlighted progress on its next-generation oral MC4R agonist, saying preclinical data show improved selectivity, higher potency, and minimal MC1R activity, with an IND targeted for 1H 2027.
• Management said it is prioritizing compounds that could be best-in-class, which contributed to the decision to move away from PL7737 in favor of newer backup candidates with better selectivity and drug-like characteristics.
• Palatin reported $3.9 million in collaboration and license revenue for the quarter, driven by the Altanispac agreement, and said cash plus expected receivables should fund operations through June 30, 2027.
• Beyond the obesity pipeline, Palatin pointed to non-dilutive partnership income from Boehringer Ingelheim and Altanispac, and said its PL8177 ulcerative colitis program remains available for potential partnering after positive phase II proof-of-concept data.

Palatin Technologies Price Performance

Shares of PTN traded down $3.15 during midday trading on Wednesday, hitting $16.55. The stock had a trading volume of 30,497 shares, compared to its average volume of 22,333. Palatin Technologies has a fifty-two week low of $4.51 and a fifty-two week high of $31.00. The stock’s 50-day moving average price is $20.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PTN. Janus Henderson Group PLC acquired a new position in shares of Palatin Technologies in the fourth quarter worth about $2,195,000. Logos Global Management LP acquired a new position in shares of Palatin Technologies in the fourth quarter worth about $2,153,000. RA Capital Management L.P. acquired a new position in shares of Palatin Technologies in the fourth quarter worth about $1,077,000. Perceptive Advisors LLC acquired a new position in shares of Palatin Technologies in the fourth quarter worth about $1,077,000. Finally, Superstring Capital Management LP acquired a new position in shares of Palatin Technologies in the fourth quarter worth about $522,000. 11.50% of the stock is currently owned by institutional investors and hedge funds.

Palatin Technologies Company Profile

Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.